{"mainPropery":{"diseaseId":4475,"diseaseName":"Testotoxicosis","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/4475/testotoxicosis","synonyms":["Precocious puberty, male limited","Sexual precocity, familial, gonadotropin-independent","Pubertas Praecox","Familial Testotoxicosis (subtype)"],"synonyms-with-source":[{"name":"Precocious puberty, male limited"},{"name":"Sexual precocity, familial, gonadotropin-independent"},{"name":"Pubertas Praecox"},{"name":"Familial Testotoxicosis (subtype)"}],"identifiers":[{"identifierType":"OMIM","identifierId":"176410"},{"identifierType":"ORPHANET","identifierId":"3000"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":8,"diseaseTypeName":"Endocrine Diseases","source":"Orphanet"}],"organizations":[],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/176410' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=176410' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Testotoxicosis. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=PRECOCIOUS PUBERTY, MALE-LIMITED' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Testotoxicosis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/familial-male-limited-precocious-puberty' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Testotoxicosis. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/923876-overview#showall' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3000' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:176410' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":6003,"questionText":"What is testotoxicosis?","answerText":"<strong>Testotoxicosis</strong> is a form of gonadotropin-independent <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001168.htm\" target=_blank>precocious puberty</a> in which boys experience early onset and progression of puberty. The disease generally presents between 2 and 4 years of age. Patients have accelerated growth, early development of secondary sexual characteristics and reduced adult height. Testotoxicosis is caused by an activating mutation of the <a href=\"http://omim.org/entry/152790\" target=_blank>luteinizing hormone receptor</a> (LHCGR) gene, which leads to increased levels of sex steroids in the context of low luteinizing hormone. The condition may be sporadic or transmitted as a <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=_blank>dominant</a> trait. It is only&nbsp;expressed in males.[5002][5003][5004][5005] Treatment consists of reducing hyperandrogenism in children (sexual maturation, stature), with <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682816.html\" target=_blank>ketoconazole</a> or a combination of antiandrogens and aromatase inhibitors.[5005] ","dateModified":"2012-02-29T17:37:00"},"basicQuestions":[{"questionId":6006,"questionText":"What is the prognosis for boys diagnosed with testotoxicosis?","answerText":"The complications associated with testotoxicosis are&nbsp;related to early sexual and physical maturation. Other complications are psychological and related to the early sexual and physical maturation. In general, prognosis is excellent with proper treatment.[5004]","dateModified":"2012-02-29T17:33:00","resourceClassificationName":"Prognosis","references":[{"referenceId":5004,"authors":"Ferry RJ, Fenton CL, Poth MPM","articleTitle":"Precocious Pseudopuberty","bookWebsiteJournalTitle":"eMedicine","date":"2009","url":"http://emedicine.medscape.com/article/923876-overview","dateAccessed":"2012-02-29T00:00:00"}]},{"questionId":6004,"questionText":"How might testotoxicosis be treated?","answerText":"Decisions regarding treatment for patients with testotoxicosis are complex.[5004] Treatment typically consists of reducing hyperandrogenism in children (sexual maturation, stature) with <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682816.html\" target=_blank>ketoconazole</a> or a combination of antiandrogens and aromatase inhibitors.[5004][5005]&nbsp;Recently, the use of combination therapy with <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a697047.html\" target=_blank>bicalutamide</a> (a potent antiandrogen agent)&nbsp;and <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a696018.html\" target=_blank>anastrozole</a> or <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a698004.html\" target=_blank>letrozole</a> (third-generation aromatase inhibitors)&nbsp;was reported to yield encouraging short-term results, including slower growth rate.[5006][5007]&nbsp;","dateModified":"2012-02-29T17:28:00","resourceClassificationName":"Treatment","references":[{"referenceId":5004,"authors":"Ferry RJ, Fenton CL, Poth MPM","articleTitle":"Precocious Pseudopuberty","bookWebsiteJournalTitle":"eMedicine","date":"2009","url":"http://emedicine.medscape.com/article/923876-overview","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5005,"authors":"Carel JC","articleTitle":"Testotoxicosis","bookWebsiteJournalTitle":"Orphanet","date":"2005","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=3000","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5006,"authors":"Lenz AM, Shulman D, Eugster EA, Rahhal S, Fuqua JS, Pescovitz OH, Lewis KA","articleTitle":"Bicalutamide and third-generation aromatase inhibitors in testotoxicosis","bookWebsiteJournalTitle":"Pediatrics","date":"2010","url":"http://www.ncbi.nlm.nih.gov/pubmed/20713483","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5007,"authors":"Reiter EO, Mauras N, McCormick K, Kulshreshtha B, Amrhein J, De Luca F, O'Brien S, Armstrong J, Melezinkova H","articleTitle":"Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT)","bookWebsiteJournalTitle":"J Pediatr Endocrinol Metab","date":"2010","url":"http://www.ncbi.nlm.nih.gov/pubmed/21158211","dateAccessed":"2012-02-29T00:00:00"}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":34092,"abbreviatedInquiry":"My uncle, my brother, and&nbsp;one of&nbsp;my brother's&nbsp;sons have testotoxicosis. My son is also affected. I took my son to an endocrinologist and he treated my son with ketoconazole. Treatment was stopped when my son was&nbsp;11 years old.&nbsp;He continued to grow until the age of 13. Now he is 14 and is 5'7\".&nbsp; We are in the process of going back to the doctor that treated my son to get an x-ray of his hand to see if the growth plates have grown together. Has&nbsp;ketoconazole been proven to work successfully in boys with testotoxicosis?","caseQuestions":[{"questionId":6003,"questionText":"What is testotoxicosis?","answerText":"<strong>Testotoxicosis</strong> is a form of gonadotropin-independent <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001168.htm\" target=_blank>precocious puberty</a> in which boys experience early onset and progression of puberty. The disease generally presents between 2 and 4 years of age. Patients have accelerated growth, early development of secondary sexual characteristics and reduced adult height. Testotoxicosis is caused by an activating mutation of the <a href=\"http://omim.org/entry/152790\" target=_blank>luteinizing hormone receptor</a> (LHCGR) gene, which leads to increased levels of sex steroids in the context of low luteinizing hormone. The condition may be sporadic or transmitted as a <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=_blank>dominant</a> trait. It is only&nbsp;expressed in males.[5002][5003][5004][5005] Treatment consists of reducing hyperandrogenism in children (sexual maturation, stature), with <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682816.html\" target=_blank>ketoconazole</a> or a combination of antiandrogens and aromatase inhibitors.[5005] ","dateModified":"2012-02-29T17:37:00","references":[{"referenceId":5002,"authors":"Reiter EO, Norjavaara E.","articleTitle":"Testotoxicosis: current viewpoint","bookWebsiteJournalTitle":"Pediatr Endocrinol Rev","date":"2005","url":"http://www.ncbi.nlm.nih.gov/pubmed?term=16361981","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5003,"authors":"Brito VN, Latronico AC, Arnhold IJ, Mendonca BB","articleTitle":"Update on the etiology, diagnosis and therapeutic management of sexual precocity","bookWebsiteJournalTitle":"Arq Bras Endocrinol Metabol","date":"2008","url":"http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302008000100005&lng=en&nrm=iso&tlng=en","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5004,"authors":"Ferry RJ, Fenton CL, Poth MPM","articleTitle":"Precocious Pseudopuberty","bookWebsiteJournalTitle":"eMedicine","date":"2009","url":"http://emedicine.medscape.com/article/923876-overview","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5005,"authors":"Carel JC","articleTitle":"Testotoxicosis","bookWebsiteJournalTitle":"Orphanet","date":"2005","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=3000","dateAccessed":"2012-02-29T00:00:00"}]},{"questionId":6004,"questionText":"How might testotoxicosis be treated?","answerText":"Decisions regarding treatment for patients with testotoxicosis are complex.[5004] Treatment typically consists of reducing hyperandrogenism in children (sexual maturation, stature) with <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682816.html\" target=_blank>ketoconazole</a> or a combination of antiandrogens and aromatase inhibitors.[5004][5005]&nbsp;Recently, the use of combination therapy with <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a697047.html\" target=_blank>bicalutamide</a> (a potent antiandrogen agent)&nbsp;and <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a696018.html\" target=_blank>anastrozole</a> or <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a698004.html\" target=_blank>letrozole</a> (third-generation aromatase inhibitors)&nbsp;was reported to yield encouraging short-term results, including slower growth rate.[5006][5007]&nbsp;","dateModified":"2012-02-29T17:28:00","resourceClassificationName":"Treatment","references":[{"referenceId":5004,"authors":"Ferry RJ, Fenton CL, Poth MPM","articleTitle":"Precocious Pseudopuberty","bookWebsiteJournalTitle":"eMedicine","date":"2009","url":"http://emedicine.medscape.com/article/923876-overview","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5005,"authors":"Carel JC","articleTitle":"Testotoxicosis","bookWebsiteJournalTitle":"Orphanet","date":"2005","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=3000","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5006,"authors":"Lenz AM, Shulman D, Eugster EA, Rahhal S, Fuqua JS, Pescovitz OH, Lewis KA","articleTitle":"Bicalutamide and third-generation aromatase inhibitors in testotoxicosis","bookWebsiteJournalTitle":"Pediatrics","date":"2010","url":"http://www.ncbi.nlm.nih.gov/pubmed/20713483","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5007,"authors":"Reiter EO, Mauras N, McCormick K, Kulshreshtha B, Amrhein J, De Luca F, O'Brien S, Armstrong J, Melezinkova H","articleTitle":"Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT)","bookWebsiteJournalTitle":"J Pediatr Endocrinol Metab","date":"2010","url":"http://www.ncbi.nlm.nih.gov/pubmed/21158211","dateAccessed":"2012-02-29T00:00:00"}]},{"questionId":6005,"questionText":"Has&nbsp;ketoconazole been proven to work successfully with boys with testotoxicosis?&nbsp;","answerText":"<a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682816.html\" target=_blank>Ketoconazole</a> blocks enzymes in the steroid biosynthetic pathway. It primarily inhibits C-17,29-desmolase, the enzyme responsible for androstenedione biosynthesis. This medication, which is more commonly used&nbsp;for treating fungal infections, may be used in treating precocious pseudopuberty. It inhibits steroid synthesis at the level of 17 á -hydroxylase/17,20-lyase, a key enzyme in sex steroid production. It also inhibits testosterone binding to its binding globulin.[5004]&nbsp;Long-term treatment with ketoconazole appears to significantly decreased the bone age/chronological age ratio without&nbsp;significant side-effects in boys with testotoxicosis</span>. However,&nbsp;this therapy shows limited efficacy in attaining normal adult height.[5008] ","dateModified":"2012-02-29T17:36:00","references":[{"referenceId":5004,"authors":"Ferry RJ, Fenton CL, Poth MPM","articleTitle":"Precocious Pseudopuberty","bookWebsiteJournalTitle":"eMedicine","date":"2009","url":"http://emedicine.medscape.com/article/923876-overview","dateAccessed":"2012-02-29T00:00:00"},{"referenceId":5008,"authors":"Almeida MQ, Brito VN, Lins TS, Guerra-Junior G, de Castro M, Antonini SR, Arnhold IJ, Mendonca BB, Latronico AC","articleTitle":"Long-term treatment of familial male-limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole","bookWebsiteJournalTitle":"Clin Endocrinol (Oxf)","date":"2008","url":"http://www.ncbi.nlm.nih.gov/pubmed/18088394","dateAccessed":"2012-02-29T00:00:00"}]},{"questionId":6006,"questionText":"What is the prognosis for boys diagnosed with testotoxicosis?","answerText":"The complications associated with testotoxicosis are&nbsp;related to early sexual and physical maturation. Other complications are psychological and related to the early sexual and physical maturation. In general, prognosis is excellent with proper treatment.[5004]","dateModified":"2012-02-29T17:33:00","resourceClassificationName":"Prognosis","references":[{"referenceId":5004,"authors":"Ferry RJ, Fenton CL, Poth MPM","articleTitle":"Precocious Pseudopuberty","bookWebsiteJournalTitle":"eMedicine","date":"2009","url":"http://emedicine.medscape.com/article/923876-overview","dateAccessed":"2012-02-29T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":15063,"phenoTypeName":"Accelerated skeletal maturation","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10943,"phenoTypeName":"Male infertility","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":6031,"phenoTypeName":"Precocious puberty","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10035,"phenoTypeName":"Tall stature","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":4755,"phenoTypeName":"Abnormal hair morphology","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9328,"phenoTypeName":"Acne","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":6544,"phenoTypeName":"Long penis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4486,"phenoTypeName":"Attention deficit hyperactivity disorder","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6453,"phenoTypeName":"Macroorchidism","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14167,"phenoTypeName":"Oligospermia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4662,"phenoTypeName":"Decreased testicular size","percentRanges":"-"},{"phenoTypeId":1372,"phenoTypeName":"Precocious puberty in males","percentRanges":"-"},{"phenoTypeId":10458,"phenoTypeName":"Sex-limited autosomal dominant","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Testotoxicosis"}